COVID-19相关凝血病与炎症反应:已知与知识缺口
COVID-19患者常出现凝血病,血栓事件发生率高,导致不良结局。D-二聚体、纤维蛋白原、血小板计数、白细胞介素-6、淋巴细胞计数及SOFA、ISTH DIC、SIC等评分有助于预测临床病程、医疗资源需求及患者结局,但治疗仍限于非特异性支持治疗;黏弹性检测的价值尚不明确,正在研究中。
要点
- COVID-19相关凝血病与高血栓事件发生率和不良结局相关。
- D-二聚体、纤维蛋白原、血小板计数、IL-6、淋巴细胞计数及SOFA、ISTH DIC、SIC评分有助于预测临床病程和资源需求。
- 治疗仍限于非特异性支持治疗,黏弹性检测的价值尚不明确,正在研究中。
核心结论
- COVID-19相关凝血病与高血栓事件发生率和不良结局相关,但治疗选择有限,黏弹性检测的价值尚未明确。
研究设计与样本
- 本文为综述,总结COVID-19相关凝血病的已知知识与知识缺口。
主要发现
- COVID-19患者常出现凝血病,血栓事件发生率高,导致不良结局。
- D-二聚体、纤维蛋白原、血小板计数、IL-6、淋巴细胞计数及SOFA、ISTH DIC、SIC评分有助于预测临床病程、医疗资源需求(如ICU床位、插管和呼吸机治疗、ECMO)及患者结局。
- 治疗选择目前限于非特异性支持治疗。
- 黏弹性检测在预测临床病程、医疗资源需求、患者结局或指导抗凝治疗中的额外价值尚不明确,正在研究中(如ROHOCO研究)。
临床怎么用
- 可利用D-二聚体、纤维蛋白原、血小板计数、IL-6、淋巴细胞计数及SOFA、ISTH DIC、SIC评分辅助预测COVID-19患者的临床病程和资源需求。
- 治疗仍以非特异性支持治疗为主,黏弹性检测的应用价值待进一步研究。
局限性
- 黏弹性检测在COVID-19相关凝血病中的价值尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with coronavirus disease 2019 (COVID-19) frequently experience a coagulopathy associated with a high incidence of thrombotic events leading to poor outcomes. Here, biomarkers of coagulation (such as D-dimer, fibrinogen, platelet count), inflammation (such as interleukin-6), and immunity (such as lymphocyte count) as well as clinical scoring systems (such as sequential organ failure assessment [SOFA], International Society on Thrombosis and Hemostasis disseminated intravascular coagulation [ISTH DIC], and sepsis-induced coagulopathy [SIC] score) can be helpful in predicting clinical course, need for hospital resources (such as intensive care unit [ICU] beds, intubation and ventilator therapy, and extracorporeal membrane oxygenation [ECMO]) and patient's outcome in patients with COVID-19. However, therapeutic options are actually limited to unspecific supportive therapy. Whether viscoelastic testing can provide additional value in predicting clinical course, need for hospital resources and patient's outcome or in guiding anticoagulation in COVID-19-associated coagulopathy is still incompletely understood and currently under investigation (eg, in the rotational thromboelastometry analysis and standard coagulation tests in hospitalized patients with COVID-19 [ROHOCO] study). This article summarizes what we know already about COVID-19-associated coagulopathy and-perhaps even more importantly-characterizes important knowledge gaps.
引用
- Görlinger K, Dirkmann D, Gandhi A, et al. COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps? Anesth Analg. 2020. PMID: 33079850. doi:10.1213/ANE.0000000000005147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。